In this video interview with Idoroenyi Amanam, MD, an assistant professor in City of Hope’s Division of Leukemia in the Department of Hematology and Hematopoietic Cell Transplantation, he discusses an abstract presented at ASCO 2025 titled, “Real-world outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.”
In this retrospective analysis, interim data from 103 patients were collected between October 17, 2024 and December 19, 2024. Patients were treated in two cohorts: 46 patients were treated with first-line luspatercept and 57 patients were treated with ESAs. The analysis compared first-line luspatercept, which was approved by the US Food and Drug Administration in August 2023, to ESAs in patients with LR-MDS.
“This analysis corroborates the results of the COMMANDS trial and demonstrates the favorable RW effectiveness of first-line luspatercept vs first-line ESA for anemia treatment in LR-MDS,” the authors wrote in the ASCO 2025 abstract.
